The size of the European cartilage regeneration market was valued at USD 158.73 million in 2021. It is projected to be growing at a CAGR of 15.5% and be worth USD 326.27 million by 2026.
Osteoarthritis of the knee is a cartilage disorder caused due to factors such as aging, degenerative muscular disorder, and obesity. The increasing prevalence and incidence of joint and bone diseases and the rapid growth of the senior population across European countries are contributing to the development of the European cartilage regeneration market. For example, in 2019, 12.3 million residents of Great Britain were aged 65 and over, representing 19% of the total population in the region. According to the Arthritis Foundation, in 2019, degenerative joint diseases such as osteoarthritis will affect more than 135 million patients worldwide by the year 2050.
There has been a tremendous demand for cartilage regeneration surgeries, wherein the worn-out cartilage is injected with cartilage regenerative substances. Unfortunately, the cartilage tissue has little/no ability to repair itself due to the absence of blood vessels and other factors that help with wound healing. The cartilage acts as a viscous substance between the joints as it aids in joint movement and protection. When cartilage damage occurs, the regular movement of the knee is restricted, causing immense pain. Cartilage damage, when left untreated, leads to knee replacement surgery.
The market growth is further supported by constant technological advances in medical imaging technology, such as MRI, which aid in early diagnosis and treatment. Several key market players are expanding their portfolio with high-quality cartilage repair products, which is expected to drive the European cartilage regeneration market during the forecast period. Cartilage regeneration employs advanced products such as injection plasma rich in platelets, allografts, stimulation drills, and implants. Furthermore, the localized availability of regenerative stem cells helps in the process of cellular repair and regeneration. In addition, the growing clinical trials for research and development for bone and joints disorders are expected to drive the European market.
However, there are significant restraints associated with cartilage regeneration procedures. For example, using allografts, PPRs, and stimulation drills to stimulate growth has safety concerns, such as immune rejection, tumor formation, delayed wound healing. Moreover, strict regulations are also expected to hamper market growth.
This research report on the European cartilage regeneration market has been segmented and sub-segmented into the following categories:
By Type Of Treatment:
By Application:
By Country:
The German cartilage regeneration market is predicted to dominate the European market and grow at a CAGR of 4.8% during the forecast period. The UK market is expected to experience a CAGR of 4.5%. Additionally, the French market is expected to experience a CAGR of 4%. As a result, Germany is anticipated to be valued at over US $ 79 million by 2025.
The increasing number of cartilage regeneration procedures in the UK is on the rise owing to excellent reimbursement rules. The other factors are the growth of the senior population, the increasing research and development funds, rising incidence of osteoarthritis are expected to help the regional market growth. According to Arthritis Research UK, estimates of rheumatoid arthritis stand at around 405,000. In addition, increased product adoption, the increasing prevalence of obesity and diabetes lead to bone degeneration and joint disease. These factors are believed to provide growth opportunities in the UK region during the forecast period.
Italy aims to grow at the highest CAGR during the forecast period attributed to the increasing technological advancements and a favorable environment for R&D establishments. Moreover, the growing incidence of sports activities and traumatic accidents will contribute to the market's growing demand under study. Concerning the statement mentioned above, in the year 2019, Italy recorded 175,000 traffic accidents. The rest of the other European regions are also expected to gain good market growth due to international biopharmaceutical companies and research institutes in Europe.
KEY MARKET PLAYERS:
A few of the notable companies leading the Europe cartilage regeneration market profiled in the report are Zimmer Biomet Holdings, Inc. (U.S.), Vericel Corporation (U.S.), Smith & Nephew plc (U.K.), Osiris Therapeutics, Inc. (U.S.), and Arthrex Inc. (U.S.).
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Type of Treatment
5.1.1 Introduction
5.1.2 Cell Based Approaches
5.1.2.1 Stem Cells
5.1.2.2 Growth Factor Technology
5.1.2.3 Chondrocyte Transplantation
5.1.3 Non-Cell Based Approaches
5.1.3.1 Cell Free Composites
5.1.3.2 Tissue Scaffolds
5.1.4 Y-o-Y Growth Analysis, By Type of Treatment
5.1.5 Market Attractiveness Analysis, By Type of Treatment
5.1.6 Market Share Analysis, By Type of Treatment
5.2 Application
5.2.1 Introduction
5.2.2 Hyaline Cartilage Regeneration
5.2.3 Fibrocartilage Regeneration
5.2.4 Y-o-Y Growth Analysis, By Application
5.2.5 Market Attractiveness Analysis, By Application
5.2.6 Market Share Analysis, By Application
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Type of Treatment
6.1.3.3 By Application
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Type of Treatment
6.1.4.3 By Application
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Type of Treatment
6.1.5.3 By Application
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Zimmer Biomet Holdings
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Vericel Corporation
8.3 Smith & Nephew
8.4 Osiris Therapeutics
8.5 Arthrex
9.Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Appendix
Related Reports
